Results: Thirty-five patients were included. Of these, 14 in left ventricular mass (LVM) in hypertensive patients patients (40%) were not previously treated. Inter-and with left ventricular hypertrophy under drug therapy intra-observer variability for LVMI measurement were with once-daily slow-release diltiazem. Magnetic reson-5.6 ± 4.3% and 2.1 ± 3.0%, respectively. Mean baseline ance imaging (MRI) was used for this purpose because LVMI was 110 ± 16 g/m 2 in male and 96 ± 16 g/m 2 in of its higher reproducibility than M-mode or twofemale patients. It decreased by 3.6% at M 3 (P = 0.05) dimensional echocardiography. and by 6.0% at M 6 (P = 0.02). A trend towards a greater Methods: Patients suffering from essential hyperten-LVMI reduction was observed in previously untreated sion were included if their baseline LVM index (LVMI) patients. was у105g/m 2 in male or у85 g/m 2 in female patients,
Introduction
lation of this compound (once-daily SR diltiazem) Left ventricular hypertrophy (LVH) has been shown has been recently developed. 6, 7 Plasma concento be one of the most frequent features of essential trations following intake of this formulation remain hypertension and to be associated with a higher within the therapeutic range over more than 24 h incidence of clinical events including sudden death, and daily fluctuations are less than with the t.i.d. often related to ventricular arrhythmia.
1 From echostandard formulation. 8, 9 Echocardiography has cardiographic studies, the prevalence of increased shown that standard diltiazem can induce LVM left ventricular mass (LVM) in hypertensive patients regression in hypertensive patients with markedly has been reported to range from 17-39% depending increased LVM. [10] [11] [12] [13] The aim of the present study on the definition. 2 A recent study has suggested that was to monitor LVM changes in hypertensive reversal of increased LVM can reduce cardiovascupatients with moderate LVM increase and treated for lar risk irrespective of age and sex. 3 It is thus of 6 months exclusively with once-daily SR diltiazem. interest to test for the ability of antihypertensive Because of its availability, echocardiography is drugs not only to normalise blood pressure (BP) but widely used to assess LVM. However, there are some also to reduce LVH.
limitations to its use: a proportion of unreadable traDiltiazem is a non-dihydropyridine calcium chancings due to unechogenicity or poor quality reported nel blocker that compares favourably with other to be about 15-25%; 1,2 and especially an intraleading antihypertensive agents in terms of efficacy observer variability of about 10% for LVM assessment, 2,14,15 ie, equal to or higher than the LVM reduction usually observed under antihypertensive Correspondence: Dr Gérald Roul, Cardiology Department, Hôpi-therapy. The latter led us to consider, for the purtaux Universitaires de Strasbourg-Hôpital de Hautepierre, measurement of LVM. [15] [16] [17] [18] The true volumetric each visit three readings were performed at intervals of at least 5 min after a resting period in the supine assessment of LVM provided by MRI might at least partially explain its potential value in this setting.
position and the mean adopted. BP always had to be read on the same arm and by the same physician using a mercury sphygmomanometer and the first
Patients and methods
and fifth Korotkoff sounds. BP was considered controlled if supine DBP either fell below 90 mm Hg or Study design was reduced by at least 10% under therapy. Patients were considered for selection by general practitioners in the area of Strasbourg (France) from MRI March 1993 to June 1994. They entered a 2-week placebo run-in period to ensure they had stable high Data were acquired using a 0.5 Tesla cryogenic sys-BP and to enable eligibility criteria to be verified tem (MR-Max, General Electric, Milwaukee, WI, using MRI and standard laboratory tests. At the end USA) according to a procedure experimentally valiof the run-in period, included patients underwent a dated by Shapiro et al in the dog 16 and by Ostrzega resting 12-lead electrocardiogram (ECG) and a cliniet al in man. 17 True short-axis ECG gated spin echo cal examination. They were given antihypertensive with an echo delay of 25 msec was used following therapy consisting exclusively of once-daily SR axial and long-axis scout views. Eight to 12 parallel diltiazem 300 mg. Follow-up visits took place after slices, each 10 mm thick and spaced 1.2 mm apart 1 month (M 1 ), 3 months (M 3 ), and 6 months (M 6 ) of were recorded so that the whole LV was encomtherapy. MRI was performed at M 3 and M 6 in passed ( Figure 1 ). In a given patient, the same douaddition to M 0 . The design of the present study was ble angulation was selected on each examination as approved by the Committee on Human Research of well as the same parameters, ie, number of slices, the Louis Pasteur University in Strasbourg. Written interslice gap, and timing within the cardiac cycle. informed consent was obtained from all patients
Images were obtained on an asymmetric matrix (256 after they had been provided with a detailed frequency encoding steps × 160 phase encoding description of the study procedure. steps), in a field of view of 42 cm, and with two exci-
Patients
Patients of either sex aged 30-75 years were included if they met all the following criteria:
(1) supine diastolic BP (DBP) in the 95-115 mm Hg range and supine systolic BP (SBP) below 200 mm Hg; (2) a baseline LVM index (LVMI) Ͼ105 g/m 2 in male or 85 g/m 2 in female patients, ie, the median values observed in our institution in hypertensive patients; (3) patients either not receiving antihypertensive therapy, or if previous drug treatment results to be not effective; and (4) patients free from other significant medical disease, previous myocardial infarction and any disease that could potentially induce hypertension.
Patients were excluded if they met at least one of the following criteria: (1) MRI contraindicated (presence of pacemaker or any metallic object inside the body, weight over 100 kg, claustrophobia); (2) diltiazem contraindicated (sick sinus syndrome, second or third-degree atrioventricular block, clinical evidence of heart failure, resting heart rate below 50 beats per minute (bpm), severe hepatic or renal failure, premenopausal women of childbearing potential or known hypersensitivity to the drug); (3) ECG within the past 3 months either not done, not available, or unreadable due to bundle branch block or accessory conduction pathway as in WolffParkinson-White syndrome; (4) patients thought unlikely to adhere to follow-up because of psychosocial or geographical problems; and (5) patients unwilling to give informed consent. Hypertension had to be present on at least three conarea is then divided by BSA, multiplied by the interslices gap (1.2 mm) and by 1.05, ie, the density of the myocardial tissue.
High BP
secutive visits separated by 2 weeks or more. At tations for each phase encoding step. The 'no phase Compliance and missing data wrap' option of the system was used which gave an One patient at M 1 and three patients at M 3 were isotropic 1.6 mm in-plane resolution. Acquisition withdrawn from the study because of uncontrolled encompassed 320 heart beats. The examination BP. One patient at M 1 and another at M 6 were lost lasted less than 15 min.
to follow-up. No MRI data had to be rejected because Data analysis consisted in delineating epicardial of poor quality or any other reason. and endocardial edges using a trackball and assessing the myocardial surface area of each slice BP and heart rate by computer assisted planimetry. LVM was obtained by multiplying surface areas by slice thickness and Baseline supine SBP and DBP were 158 ± 16 mm Hg by 1.05 g/cm 3 (the density of the myocardial tissue). and 103 ± 6 mm Hg, respectively. Both supine SBP LVMI was calculated by dividing LVM by the body and supine DBP decreased significantly (P Ͻ 0.001) surface area. LVMI at M 0 was assessed unblinded in under therapy with once-daily SR diltiazem (Table a first step, immediately after data acquisition, in 1). SBP decreased from 158 ± 16 mm Hg at M 0 to order to check whether this inclusion criterion was 144 ± 17 mm Hg at M 3 and 143 ± 14 mm Hg at M 6 met. Subsequently, raw data at M 0 , M 3 , and M 6 were and DBP from 103 ± 6 mm Hg at M 0 to 88 ± 10 stored on magnetic tapes. In order to minimise intramm Hg at M 3 and 82 ± 9 at M 6 . Baseline supine heart observer variability, LVMI values at M 0 , M 3 , and M 6 rate was 77 ± 13 beats/min. At M 3 it was 71 ± 8 were assessed later, on the same day, in a randombeats/min and at M 6 72 ± 12 beats/min (not signifiised order, by a blind observer under control of an cant, P = 0.08 and P = 0.24, respectively). external auditor.
LVM measurements Statistical methods
Based on paired measurements inter-and intraobserver variability were 5.6 ± 4.3% (n = 58; Figure All analyses were performed on an intent-to-treat 2) and 2.1 ± 3.0% (n = 28), respectively. LVMI basis. Results are expressed as mean ± standard changes under therapy are summarised in decreased significantly according to time (P = 0.05). used to assess the effect of previous antihypertenMean LVMI reduction was 3.6% at M 3 (P = 0.05) and sive therapy and time on BP and LVMI reduction.
6.0% at M 6 (P = 0.02). Differences between preWhen applicable, linear correlation tests with the viously untreated (n = 14) and previously treated Bonferroni's correction were used to assess the patients (n = 21) were not significant, although there relationship between quantitative parameters. Sigwas a trend toward a greater LVMI reduction in the nificance was set at P Ͻ 0.05. Inter-and intrasubgroup of previously untreated patients compared observer variability were assessed by dividing absolto previously treated ones (9.3% vs 3.4% at M 6 ). No ute differences between two measurements by interaction was observed between the two factors: their means.
time and existence of previous antihypertensive therapy.
Results

Study population Study of correlations
Except for baseline body weight (r = 0.43, P = 0.01), Seventy-two patients completed the 2-week placebo no correlation was observed between LVMI run in period. At the end of this period, 37 patients reduction and any parameter that could potentially were excluded for at least one of the following have interfered with it, ie, age, baseline LVMI, basereasons: (1) baseline LVMI lower than stipulated line SBP, baseline DBP, or magnitude of SBP and cut-off levels (n = 35); (2) MRI contraindicated in DBP reduction under therapy. one patient (presence of a metallic splinter in one eye); and (3) consent withdrawn by one patient. The remaining 35 patients were included. Of these, 20 Safety were males. Patients mean age was 51 ± 12 years Twelve patients (34%) volunteered at least one (range 30-73), and their body weight was 77 ± 12 kg.
adverse event. None of them was serious enough to The length of time since first diagnosis of hypertencause withdrawal from the study. They consisted of sion was 78 ± 82 months. Other cardiovascular risk headache (n = 2), vertigo (n = 3), palpitations (n = factors were smoking in 11 patients (31%), over-1), flushing (n = 6), ankle oedema (n = 2), back pain weight in 12 (34%), hypercholesterolemia in 14 (n = 1), tremor (n = 1), dizziness (n = 2), tinnitus (40%), diabetes mellitus in five (14%), family hisaurium (n = 1), shivering (n = 1), nausea (n = 1), tory of coronary artery disease in seven (2%), and a phobic reaction (n = 1), and constipation (n = 1). family history of hypertension in 14 (40%). Fourteen patients (40%) had not received any antihypertensive therapy prior to inclusion (previously Discussion untreated patients), whereas the remaining 21 (60%)
Comparison with previous studies had been previously treated with a single antihypertensive drug other than diltiazem. Body weight did
The 6% LVMI reduction demonstrated by MRI in hypertensive patients treated for 6 months exclusnot vary significantly during the course of the study. ively with once-daily SR diltiazem is slightly lower such a design is regression to the mean. In order to minimise this bias, statistical analysis was perforthan the LVMI reduction on diltiazem found using echocardiography [10] [11] [12] [13] (see Table 2 ). Amadeo et al 10 med only with blinded measurements. Furthermore, tapes were read on the same day for a given patient reported a 10% LVM regression (P Ͻ 0.01) despite the small sample size of their series (n = 10) and and by the same observer blinded to the order of data acquisition, and under control of an external short duration of treatment (1 month). Weiss et al 11 reported a 17% LVMI reduction (P Ͻ 0.005) in auditor. Although this approach is of great interest it has been adopted in only a small number of studpatients treated for 6 months with twice-daily SR diltiazem (n = 17) in a randomised double-blind ies and in particular not in the TOMHS study. 22 Our sample size (n = 35) is small. Nevertheless, it study vs propranolol (n = 23). A trend was observed in favour of diltiazem in the between-group analysis compares favourably with that of previous studies with diltiazem (Table 2) or with other antihyperten-(P = 0.06). Szlachcic et al 12 reported a 10% LVMI reduction (P Ͻ 0.05) as early as the 4th month of sive agents (mean = 15.7 patients/study). 19 Bearing this in mind, one cannot reduce the value of the therapy in patients on t.i.d. diltiazem (n = 13) whereas placebo treated patients showed no change results we report herein. The proportion of previously untreated patients is higher in the present (n = 11). The 2% LVM regression reported by Senda et al 13 in nine patients was significant only for wall study than in previous ones 19 (40% vs a mean of 28%). There was a trend in favour of greater LVM thickness regression. The relatively small LVMI reduction could be explained by the small sample regression in this subgroup which is consistent with published data, 19 underlining that it is likely that size, the low diltiazem dosage (180 mg/day), and the long history of hypertension required for inclusion the potential for further reversing increased LVM in previously treated patients is lower. (у10 years).
In Dalhö f et al meta-analysis, 19 LVM regression In the present study, mean LVMI values at baseline, 110 ± 16 g/m 2 in male and 96 ± 16 g/m 2 in appeared greater in patients on angiotensinconverting enzyme (ACE)-inhibitors than on calfemale patients, were below the values at baseline reported in studies with diltiazem (Table 2) and cium channel blockers, beta-blockers, or diuretics: 15% vs 8.5%, 8%, and 11.3%, respectively. Cruickother antihypertensive agents. The proportion of patients with LV hypertrophy as defined by shank et al 20 reached the same conclusion, but not Schmieder et al 21 whose more recent meta-analysis Devereux et al, 24 LVMI Ͼ134 g/m 2 in male and Ͼ110 g/m 2 in female patients, was also lower: 11% included only high quality studies. The authors concluded that ACE inhibitors and calcium channel vs 15-20%. This could be explained by the relatively low LVMI cut-off levels we set for inclusion. blockers are equally effective whereas beta-blockers and diuretics are less effective. The TOMHS study 22 As a result, the proportion of included patients was high compared to the prevalence of increased LVM is the only large scale, placebo controlled study available so far. Lifestyle changes plus either drugs in hypertensive patients: 2 49% vs 17-39%. These LVMI cut-off levels should be taken into account belonging to each of the five leading antihypertensive classes or placebo were prescribed for 844 when comparing studies since the higher they are, the greater the potential for LVMI reduction in patients for an average of 4.4 years. None of the drugs proved to be more effective than lifestyle patients under therapy. 21, 25 changes alone and the observed LVM regression measured by echocardiography being in the range MRI 10-15% as early as the 3rd month in each of the treatment groups. The onset of the effect of SR diltiaThe relatively low mean baseline LVMI values in the present study may also result, at least in part, from zem in the present study (LVM regression as early as the 3rd month of therapy) is consistent with pubthe use of MRI. In a previous study 26 we showed that LVM measurements were consistent with necropsy lished data with diltiazem (see Table 2 ) and with the TOMHS study. 22 findings, 146 ± 33 g vs 148 ± 37 g (r = 0.94, n = 15). In contrast, the Penn convention can overestimate true LVMI by approximately 6%. 27 Moreover, we Study design have also observed an 8% difference in mean LVMI values between MRI and echocardiography 16 and The design of the present study was open label as were most of the studies published so far. According this has also been confirmed by others. 28 These aspects could account for the discrepancies between to Herpin et al 23 the principal potential bias with 
Conclusion
ial interfaces is easier with MRI than with echocardiography providing a better assessment of wall surIn this study we were able to demonstrate that MRI face area. Finally, the field of view of MRI allows is well suited for measuring therapy induced the selection of true short-axis incidence without changes in LVM in hypertensive patients. Inter-and the limit of an acoustic window.
intra-observer variability were lessened by blind High reproducibility of LVM measurement with reading of the tapes under the control of an external MRI, owing to its true volumetric approach, has auditor. A significant LVM regression was observed been emphasised by several authors. [15] [16] [17] [18] In the as early as the 3rd month of treatment in hypertenpresent study inter-and intra-observer variability sive patients receiving exclusively once-daily SR were quite low (5.6 ± 4.3% and 2.1 ± 3.0%, diltiazem even though most of the included patients respectively), further confirming these previous had only a moderate increased LVM at baseline. results. This, together with the 6% LVMI reduction Moreover, this report further confirmed the safety of that we achieved with once-daily SR diltiazem the drug. strongly supports the choice of MRI for our purpose. Only one report dealing with the volumetric assess- 
